Division of Gastroenterology

Paul Moayyedi


Professor, Division of Gastroenterology, Department of Medicine

Richard Hunt/AstraZeneca Chair

Administrative Assistant: Lisa Dunlop
905.521.2100 X76764



Academic Biography

Dr Paul Moayyedi qualified from Bristol University in 1988 and trained in Gastroenterology at Leeds’ General Infirmary, UK under the mentorship of Professor Axon.  He was awarded a PhD in 1999 and a Masters in Public Health in 2000, both from the University of Leeds.  He was appointed Professor of Gastroenterology Health Services Research at the University of Birmingham in 2001 and then moved to McMaster University, Hamilton, Canada to be the first recipient of the Richard Hunt/AstraZeneca Chair of Gastroenterology in 2004.  He became Director of the Division of Gastroenterology at McMaster in 2006. 

Dr Moayyedi has published over 150 peer-reviewed articles and 15 book chapters.  He is a proponent of evidence based medicine and is the joint co-ordinating editor of the Upper Gastrointestinal and Pancreatic Diseases Cochrane Group.  He has been involved in the development of several national and international guidelines including the American Gastroenterology Association and the England and Wales National Institute of Clinical Excellence dyspepsia and the American College of Gastroenterology IBS guidelines.

Research Interests

His research interests include Barrett’s surveillance, population H. pylori screening and treatment to prevent gastric cancer and colorectal cancer screening.   He was the lead author in a randomized controlled trial that recruited over 8000 subjects to assess the cost-effectiveness of a community H. pylori test and treat program.  He is also currently involved in a randomized trial evaluating the efficacy of aspirin and high dose acid suppression in preventing mortality in Barrett’s esophagus.

Selected Publications

  1. Ford AC., Forman D., Bailey AG, Axon AT., Moayyedi P. Irritable bowel syndrome: a 10 year natural history of symptoms and factors that influence consultation behaviour. American Journal of Gastroenterology 2008; 103: 1229-39
  2. Tse F., Liu L., Barkun AN., Armstrong D., Moayyedi P. EUS: a meta-analysis of test performance in suspected choledocholithiasis. Gastrointestinal Endoscopy 2008; 67:235-44.
  3. Delaney BC., Qume M., Moayyedi P., Logan RF., Ford AC., Elliott C., McNulty C., Wilson S., Hobbs FD. Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomized controlled trial (MRC-CUBE trial). BMJ 2008; 336: 651-4.
  4. Barton PM. Moayyedi P., Talley NJ., Vakil NB., Delaney BC. A second-older simulation model of the cost-effectiveness of managing dyspepsia in the United States. Medical Decision Making 2008; 28 :44-45.
  5. Talley NJ., Fock KM., Moayyedi P., Gastric cancer consensus conference recommends Helicobacter pylori screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer. American Journal of Gastroenterology 2008 103:510-4.
  6. Moayyedi, P. Sequential regimens for Helicobacter pylori eradication. The Lancet 2007: 370; 1010-1012.
  7. Ford, AC., Forman D., Nathan J., Crocombe WD., Axon ATR., Moayyedi P. Clinical trial: knowledge of negative Helicobacter pylori status reduces subsequent dyspepsia-related resource use. Aliment Pharmacol Ther 2007: 26; 1267-1275.
  8. Fraser A. Delaney BC. Ford AC. Qume M. Moayyedi P. The Short-Form Leeds Dyspepsia Questionnaire validation study.  Alimentary Pharmacology & Therapeutics 2007; 25: 477-86.
  9. Leonard J. Marshall JK. Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression.  American Journal of Gastroenterology 2007; 102: 2047-56.
  10. Moayyedi P. Tepper J. Hilsden R. Rabeneck L. International comparisons of manpower in gastroenterology. American Journal of Gastroenterology 2007; 102: 478-81.
  11. Moayyedi P., Talley, N., Fennerty MB., Vakil N. Can the clinical history distinguish between organic and functional dyspepsia? JAMA 2006; 295: 1566-76.
  12. Moayyedi P., Talley NJ. Gastro-esophageal reflux disease. Lancet 2006; 367: 2086-2100.
  13. Vakil N. Moayyedi P. Fennerty MB. Talley NJ. Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. Gastroenterology 2006; 131: 390-401.
  14. Moayyedi P., Clues to the etiology of inflammatory bowel disease – a return to John Snow? American Journal of Epidemiology; 2006: 164; 624-626.
  15. Ford, AC., Forman D., Bailey AG., Axon ATR., Moayyedi P.  A Community Screening and Treatment Program for Helicobacter pylori Saves Money: Ten-year Follow-up of a Randomized Controlled Trial. Gastroenterology 2005; 129: 1900-1909.
  16. Ford AC., Qume M., Moayyedi P., Arents NL, Lassen AT., Logan RF., McColl KE., Myres P., Delaney BC. Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology 2005; 128: 1838-44.
  17. Talley NJ., Vakil NB., Moayyedi P. American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology 2005; 129: 1756-80.
  18. Ford AC., Forman D., Reynolds PD., Cooper B., Moayyedi P.  Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett’s esophagus.  American Journal of Epidemiology 2005; 162: 454-60.
  19. Delaney B., Moayyedi P.  Eradicating H. pylori.  Does not increase symptoms of gastro-esophageal reflux disease.  BMJ 2004; 328: 1388-9.
  20. Moayyedi P., Delaney B., Vakil N., Forman D., Talley N. The efficacy of proton pump inhibitors in non-ulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 2004; 127: 1329-37.
  21. Sharma N., Donnellan C., Preston C., Delaney B,. Duckett G., Moayyedi P.  A systematic review of symptomatic outcomes used in esophagitis drug therapy trials.  Gut 2004; 53: 58-65.
  22. Moayyedi P.  Bringing science to the art of diagnosis.  Gut 2004; 53: 627-628.
  23. Moayyedi P., Bardhan KD., Young L., Dixon MF., Brown L., Axon ATR.  The effect if Helicobacter pylori eradication on reflux symptoms in gastro-esophageal reflux disease in patients: a randomised controlled trial.  Gastroenterology 2001; 121: 1120-26.
  24. Moayyedi P., Feltbower R.,  Brown J., Mason S., Mason J., Nathan J., Richards IDG., Dowell AC., Axon ATR.  The effect of population H pylori screening and treatment on dyspepsia and quality of life in the community: results of a randomised controlled trial.  Lancet 2000; 355: 1665-1669.
  25. Moayyedi P., So S., Deeks J., Forman D., Mason J., Inns M., and Delaney B.  Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia.  BMJ 2000; 321: 659-664.